CMRX
Price
$2.81
Change
-$0.00 (-0.00%)
Updated
Dec 18, 04:08 PM (EDT)
76 days until earnings call
ENTA
Price
$5.78
Change
-$0.35 (-5.71%)
Updated
Dec 18, 04:12 PM (EDT)
49 days until earnings call
Ad is loading...

CMRX vs ENTA

Header iconCMRX vs ENTA Comparison
Open Charts CMRX vs ENTABanner chart's image
Chimerix
Price$2.81
Change-$0.00 (-0.00%)
Volume$100
CapitalizationN/A
Enanta Pharmaceuticals
Price$5.78
Change-$0.35 (-5.71%)
Volume$210
CapitalizationN/A
CMRX vs ENTA Comparison Chart
Loading...
CMRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ENTA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CMRX vs. ENTA commentary
Dec 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CMRX is a Hold and ENTA is a Hold.

COMPARISON
Comparison
Dec 19, 2024
Stock price -- (CMRX: $2.81 vs. ENTA: $6.13)
Brand notoriety: CMRX and ENTA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CMRX: 42% vs. ENTA: 128%
Market capitalization -- CMRX: $252.72M vs. ENTA: $129.92M
CMRX [@Biotechnology] is valued at $252.72M. ENTA’s [@Biotechnology] market capitalization is $129.92M. The market cap for tickers in the [@Biotechnology] industry ranges from $486.73B to $0. The average market capitalization across the [@Biotechnology] industry is $2.67B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CMRX’s FA Score shows that 0 FA rating(s) are green whileENTA’s FA Score has 1 green FA rating(s).

  • CMRX’s FA Score: 0 green, 5 red.
  • ENTA’s FA Score: 1 green, 4 red.
According to our system of comparison, both CMRX and ENTA are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CMRX’s TA Score shows that 5 TA indicator(s) are bullish while ENTA’s TA Score has 4 bullish TA indicator(s).

  • CMRX’s TA Score: 5 bullish, 5 bearish.
  • ENTA’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, ENTA is a better buy in the short-term than CMRX.

Price Growth

CMRX (@Biotechnology) experienced а +1.81% price change this week, while ENTA (@Biotechnology) price change was -29.05% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.65%. For the same industry, the average monthly price growth was +1.44%, and the average quarterly price growth was +4.25%.

Reported Earning Dates

CMRX is expected to report earnings on Mar 04, 2025.

ENTA is expected to report earnings on Feb 05, 2025.

Industries' Descriptions

@Biotechnology (-3.65% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CMRX($253M) has a higher market cap than ENTA($130M). CMRX YTD gains are higher at: 191.948 vs. ENTA (-34.857). CMRX has higher annual earnings (EBITDA): -92.74M vs. ENTA (-104.08M). ENTA has more cash in the bank: 230M vs. CMRX (136M). CMRX has less debt than ENTA: CMRX (644K) vs ENTA (50.6M). ENTA has higher revenues than CMRX: ENTA (72M) vs CMRX (159K).
CMRXENTACMRX / ENTA
Capitalization253M130M195%
EBITDA-92.74M-104.08M89%
Gain YTD191.948-34.857-551%
P/E RatioN/AN/A-
Revenue159K72M0%
Total Cash136M230M59%
Total Debt644K50.6M1%
FUNDAMENTALS RATINGS
CMRX vs ENTA: Fundamental Ratings
CMRX
ENTA
OUTLOOK RATING
1..100
3357
VALUATION
overvalued / fair valued / undervalued
1..100
87
Overvalued
95
Overvalued
PROFIT vs RISK RATING
1..100
90100
SMR RATING
1..100
9797
PRICE GROWTH RATING
1..100
3494
P/E GROWTH RATING
1..100
971
SEASONALITY SCORE
1..100
9585

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CMRX's Valuation (87) in the Biotechnology industry is in the same range as ENTA (95). This means that CMRX’s stock grew similarly to ENTA’s over the last 12 months.

CMRX's Profit vs Risk Rating (90) in the Biotechnology industry is in the same range as ENTA (100). This means that CMRX’s stock grew similarly to ENTA’s over the last 12 months.

CMRX's SMR Rating (97) in the Biotechnology industry is in the same range as ENTA (97). This means that CMRX’s stock grew similarly to ENTA’s over the last 12 months.

CMRX's Price Growth Rating (34) in the Biotechnology industry is somewhat better than the same rating for ENTA (94). This means that CMRX’s stock grew somewhat faster than ENTA’s over the last 12 months.

ENTA's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for CMRX (97). This means that ENTA’s stock grew significantly faster than CMRX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CMRXENTA
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
60%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
71%
Momentum
ODDS (%)
Bullish Trend 2 days ago
78%
N/A
MACD
ODDS (%)
Bullish Trend 2 days ago
70%
Bearish Trend 2 days ago
85%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
74%
Bearish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 8 days ago
76%
Bullish Trend 27 days ago
70%
Declines
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 6 days ago
83%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
57%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
CMRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ENTA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GAKAX10.540.01
+0.09%
AXS Merger Fd Investor
ZVNBX40.65-0.03
-0.07%
Zevenbergen Growth Investor
FSIRX8.56-0.02
-0.23%
Fidelity Advisor Strategic Real Ret I
CISIX52.54-0.25
-0.47%
Calvert US Large Cap Core Rspnb Idx I
TEGYX42.60-0.38
-0.88%
Touchstone Mid Cap Growth Y

CMRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CMRX has been loosely correlated with NAMS. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if CMRX jumps, then NAMS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CMRX
1D Price
Change %
CMRX100%
-3.44%
NAMS - CMRX
42%
Loosely correlated
+7.69%
FGEN - CMRX
35%
Loosely correlated
+7.07%
MRSN - CMRX
34%
Loosely correlated
-1.93%
ENTA - CMRX
33%
Poorly correlated
-2.85%
AXON - CMRX
32%
Poorly correlated
-2.09%
More

ENTA and

Correlation & Price change

A.I.dvisor indicates that over the last year, ENTA has been loosely correlated with NTLA. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if ENTA jumps, then NTLA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ENTA
1D Price
Change %
ENTA100%
-2.85%
NTLA - ENTA
41%
Loosely correlated
-1.87%
ABOS - ENTA
40%
Loosely correlated
-0.51%
ETNB - ENTA
39%
Loosely correlated
+1.01%
KROS - ENTA
39%
Loosely correlated
-7.31%
PGEN - ENTA
39%
Loosely correlated
+2.46%
More